Dublin, Oct. 31, 2025 (GLOBE NEWSWIRE) -- The "Catalyst Monitor: Q4 2025 Outlook" report has been added to ResearchAndMarkets.com's offering. This report compiles published, predictive intelligence ...

(MENAFN- GlobeNewsWire - Nasdaq) The report "Catalyst Monitor Q4 2025" highlights upcoming market opportunities in biotech and pharma, focusing on key approvals and trials such as Cytokinetics's ...

Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...

Q3 2025 Earnings Call Transcript October 29, 2025 GSK plc beats earnings expectations. Reported EPS is $1.48, expectations were $1.26. Operator: Ladies and gentlemen, a very warm welcome to the GSK Q3 ...

Smartphones can accurately assess neuromuscular diseases, using video and free apps that provide faster and easier way to detect diseases earlier.

The market size for emphysema in the leading markets is expected to grow significantly by 2034. The United States accounted for the highest emphysema treatment market size in 7MM in 2024, in ...

Emma Walmsley and her GSK CEO successor, Luke Miels, are safeguarding the British pharma’s 40 billion-pound-sterling sales projection for 2031 on the back of a strong quarter. The GSK executives are ...

The emphysema market is anticipated to grow steadily, fueled by a range of emerging therapies under development. Leading candidates like SAR447537 (Sanofi), Alvelestat (Mereo BioPharma), BEAM-302 ...